Amgen Business Development
Investment Details
Investor Type
Corporate VC
Asset Class Focus
Venture Capital
Stage Focus
Early Stage, Growth, Late Stage
Geographical Focus
United States, Canada, Japan, Australia, Europe, Asia, China, India, Brazil, United Arab Emirates, Mexico, South Korea, Saudi Arabia, Egypt, South Africa, Israel, Chile, Argentina, Colombia, Peru
Industries Focus
- Healthcare
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Regenerative Medicine
- Oncology
- Immunology
- Genomics
- Rare Diseases
- Cardiovascular
- Neuroscience
- Cell Therapy
- Gene Therapy
Investment Size:
5,000,000 to 50,000,000 USD
Investor Details
Amgen Business Development is the corporate venture capital arm of Amgen Inc., focusing on investments in biotechnology and life sciences companies. The team brings together deep scientific, financial, deal, partnership, and integration expertise to identify and support innovative companies that align with Amgen's strategic interests. Their investments aim to advance Amgen's mission of delivering innovative medicines to patients worldwide.
The investment strategy encompasses a broad range of stages, from early-stage startups to more mature companies, with investment sizes typically ranging from $5 million to $50 million. Geographically, Amgen Business Development targets regions including the United States, Europe, Asia, Australia, Canada, Japan, South Korea, China, India, Brazil, Mexico, Argentina, Chile, Colombia, Peru, South Africa, Egypt, Saudi Arabia, United Arab Emirates, and Israel.
Industries of interest include biotechnology, pharmaceuticals, healthcare, medical devices, diagnostics, digital health, genomics, immunology, oncology, cardiovascular, neuroscience, rare diseases, regenerative medicine, cell therapy, and gene therapy. This diverse focus reflects Amgen's commitment to advancing science and improving patient outcomes across a wide array of therapeutic areas.
Requirements
- Innovative technologies
- Strong scientific evidence
- Alignment with Amgen's strategic interests
- Experienced management teams
- Scalable business models
- Potential for significant patient impact
Contact
[Official Website Hidden]
[HQ Location Hidden]
Portfolio Companies
- Five Prime Therapeutics
- Rodeo Therapeutics
- Teneobio
- Neumora Therapeutics
- Generate Biomedicines
- Arrakis Therapeutics
- Plexium
- BeiGene
- Kyowa Kirin
- ChemoCentryx
- Horizon Therapeutics
Mentioned In
-
$19.95
-
$9.95
-
$14.95
-
$39.95
-
$19.95
-
$24.95
-
$99.00
-
$299.00
Claim this Investor
Are you an official representative of Amgen Business Development?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim